{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T02:26:22Z","timestamp":1784168782058,"version":"3.55.0"},"reference-count":34,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2017,9,8]],"date-time":"2017-09-08T00:00:00Z","timestamp":1504828800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0184178","type":"journal-article","created":{"date-parts":[[2017,9,8]],"date-time":"2017-09-08T17:49:38Z","timestamp":1504892978000},"page":"e0184178","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":28,"title":["Serial QuantiFERON-TB Gold testing in patients with psoriasis treated with ustekinumab"],"prefix":"10.1371","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7871-8480","authenticated-orcid":true,"given":"Chuan-Yu","family":"Hsiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsien-Yi","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-Shun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsen-Fang","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2017,9,8]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent","volume":"345","author":"J Keane","year":"2001","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1002\/art.11137","article-title":"Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report","volume":"48","author":"JJ G\u00f3mez-Reino","year":"2003","journal-title":"Arthritis Rheum"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1086\/421494","article-title":"Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor","volume":"39","author":"AK Mohan","year":"2004","journal-title":"Clin Infect Dis"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"T Bongartz","year":"2006","journal-title":"JAMA"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jaad.2015.06.004","article-title":"To test or not to test? An updated evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis and psoriatic arthritis","volume":"73","author":"CS Ahn","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s12016-012-8301-7","article-title":"Biologic therapies in the treatment of psoriasis: a comprehensive evidence-based basic science and clinical review and a practical guide to tuberculosis monitoring","volume":"44","author":"RK Sivamani","year":"2013","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1164\/rccm.200402-179OC","article-title":"Specific detection of tuberculosis infection: an interferon-gamma-based assay using new antigens","volume":"170","author":"T Mori","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1128\/CDLI.6.4.606-609.1999","article-title":"Cellular immune responses to ESAT-6 discriminate between patients with pulmonary disease due to Mycobacterium avium complex and those with pulmonary disease due to Mycobacterium tuberculosis","volume":"6","author":"AD Lein","year":"1999","journal-title":"Clin Diagn Lab Immunol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1164\/rccm.200711-1613OC","article-title":"Predictive value of a whole blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis","volume":"177","author":"R Diel","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1111\/bjd.13130","article-title":"Latent tuberculosis infection in patients with chronic plaque psoriasis who are candidates for biological therapy","volume":"171","author":"P Gisondi","year":"2014","journal-title":"Br J Dermatol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1002\/art.23705","article-title":"Effectiveness of the combination of a whole-blood interferon-gamma assay and the tuberculin skin test in detecting latent tuberculosis infection in rheumatoid arthritis patients receiving adalimumab therapy","volume":"59","author":"DY Chen","year":"2008","journal-title":"Arthritis Rheum"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1093\/rheumatology\/kem064","article-title":"Use of the QuantiFERON TB Gold test as part of a screening programme in patients with RA under consideration for treatment with anti-TNF-alpha agents: the Newcastle (UK) experience","volume":"46","author":"A Pratt","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"ref13","first-page":"776","article-title":"Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population","volume":"35","author":"D Ponce de Leon","year":"2008","journal-title":"J Rheumatol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1136\/ard.2007.070789","article-title":"Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigen-specific interferon gamma assay","volume":"67","author":"G Matulis","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"ref15","first-page":"553","article-title":"Clinical experience of QuantiFERON<sup>\u00ae<\/sup> -TB Gold testing in patients with psoriasis treated with tumor necrosis factor blockers in Taiwan","volume":"164","author":"HY Chiu","year":"2011","journal-title":"Br J Dermatol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.dsi.2014.12.005","article-title":"Serial QuantiFERON-TB Gold In-Tube testing for psoriatic patients receiving antitumor necrosis factor-alpha therapy","volume":"33","author":"CY Cheng","year":"2015","journal-title":"Dermatol Sinica"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3343\/kjlm.2011.31.4.271","article-title":"Serial interferon-gamma release assays for the diagnosis of latent tuberculosis infection in patients treated with immunosuppressive agents","volume":"31","author":"KH Kim","year":"2011","journal-title":"Korean J Lab Med"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1111\/j.1468-3083.2011.04220.x","article-title":"Clinical applicability of Quantiferon-TB-Gold testing in psoriasis patients during long-term anti-TNF-alpha treatment: a prospective, observational study","volume":"26","author":"S Garcovich","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1136\/annrheumdis-2014-205376","article-title":"Frequent conversion of tuberculosis screening tests during anti-tumour necrosis factor therapy in patients with rheumatic diseases","volume":"74","author":"C Hatzara","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.jinf.2012.10.017","article-title":"Serial QuantiFERON TB-gold in-tube testing during LTBI therapy in candidates for TNFi treatment","volume":"66","author":"F Bartalesi","year":"2013","journal-title":"J Infect"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jdermsci.2011.05.005","article-title":"Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL)","volume":"63","author":"TF Tsai","year":"2011","journal-title":"J Dermatol Sci"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.smim.2006.07.010","article-title":"Inborn errors of IL-12\/23- and IFN-gamma-mediated immunity: molecular, cellular, and clinical features","volume":"18","author":"O Filipe-Santos","year":"2006","journal-title":"Semin Immunol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1111\/j.1365-2133.2012.11142.x","article-title":"The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection","volume":"167","author":"TF Tsai","year":"2012","journal-title":"Br J Dermatol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1684\/ejd.2014.2386","article-title":"Latent tuberculosis reactivation in a patient with erythrodermic psoriasis under treatment with ustekinumab and a low dose steroid, despite isoniazid chemoprophylaxis","volume":"24","author":"E Errichetti","year":"2014","journal-title":"Eur J Dermatol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1517\/14712598.2014.860441","article-title":"Usefulness of QuantiFERON<sup>\u00ae<\/sup>-TB Gold test in psoriatic patients under treatment with tumour necrosis factor blockers","volume":"14","author":"R Saraceno","year":"2014","journal-title":"Expert Opin Biol Ther"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/bjd.12544","article-title":"Interferon-\u03b3 release assay for tuberculosis in patients with psoriasis treated with tumour necrosis factor antagonists: in vivo and in vitro analysis","volume":"169","author":"I Sauzullo","year":"2013","journal-title":"Br J Dermatol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1346-8138.2010.00802.x","article-title":"Positive treatment effects of ustekinumab in psoriasis: analysis of lesional and systemic parameters","volume":"37","author":"M Reddy","year":"2010","journal-title":"J Dermatol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"4185","DOI":"10.4049\/jimmunol.174.7.4185","article-title":"Maintenance of pulmonary Th1 effector function in chronic tuberculosis requires persistent IL-12 production","volume":"174","author":"CG Feng","year":"2005","journal-title":"J Immunol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/j.1365-2133.2012.11162.x","article-title":"A case of latent tuberculosis reactivation in a patient treated with ustekinumab without concomitant isoniazid chemoprophylaxis in the PEARL trial","volume":"168","author":"TF Tsai","year":"2013","journal-title":"Br J Dermatol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1136\/annrheumdis-2011-200489","article-title":"Biphasic emergence of active tuberculosis in rheumatoid arthritis patients receiving TNF\u03b1 inhibitors: the utility of IFN\u03b3 assay","volume":"71","author":"DY Chen","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3899\/jrheum.120688","article-title":"Mycobacterial interferon-\u03b3 release variations during longterm treatment with tumor necrosis factor blockers: lack of correlation with clinical outcome","volume":"40","author":"R Scrivo","year":"2013","journal-title":"J Rheumatol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1164\/rccm.201211-2033ED","article-title":"The elusive &quot;gold&quot; standard for detecting Mycobacterium tuberculosis infection","volume":"187","author":"JD Mancuso","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"e20061","DOI":"10.1371\/journal.pone.0020061","article-title":"Unusual interferon gamma measurements with QuantiFERON-TB Gold and QuantiFERON-TB Gold In-Tube tests","volume":"6","author":"RD Powell 3rd","year":"2011","journal-title":"PLoS One"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jaad.2012.12.966","article-title":"Association between traditional systemic antipsoriatic drugs and tuberculosis risk in patients with psoriasis with or without psoriatic arthritis: results of a nationwide cohort study from Taiwan","volume":"69","author":"YJ Chen","year":"2013","journal-title":"J Am Acad Dermatol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0184178","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T20:18:11Z","timestamp":1719433091000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0184178"}},"subtitle":[],"editor":[{"given":"Paul","family":"Proost","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,9,8]]},"references-count":34,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2017,9,8]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0184178","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,8]]}}}